Microwave-Assisted Synthesis of Some 1,3,4-Oxadiazole Derivatives and Evaluation of Their Antibacterial and Antifungal Activity

Deepak Swarnkar, Rakshit Ameta, and Ritu Vyas
Department of Chemistry, PAHER University, Udaipur, Rajasthan 313003, India

Correspondence should be addressed to Deepak Swarnkar; swaranakardeepak@gmail.com
Received 10 September 2014; Revised 18 November 2014; Accepted 18 November 2014; Published 3 December 2014

1. Introduction

Oxadiazole has occupied a unique place in the field of medicinal and pesticide chemistry due to its wide range of activities. Bhandari et al. [1] have reported the design, synthesis, and evaluation of anti-inflammatory, analgesic, and ulcerogenicity of novel S-substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives whereas Narayana et al. [2] have synthesized some new 2-(6-methoxy-2-naphthyl)-5-aryl-1,3,4-oxadiazoles as possible nonsteroidal anti-inflammatory and analgesic agents. Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenic, and lipid peroxidation properties of ibuprofen derivatives have been studied by Amir and Kumar [3] while Hui et al. [4] have carried out the synthesis and antibacterial activities of 1,3,4-oxadiazole derivatives containing 5-methylisoxazole moiety.

1,3,4-Oxadiazole derivatives have been synthesized by Şahin et al. [5] and they have also studied their antifungal activity. Novel chiral and achiral benzenesulfonamides bearing 1,3,4-oxadiazole moieties have been synthesized by Zareef et al. [6] and studied for their antimalarial activity. Husain and Ajmal [7] have synthesized novel 1,3,4-oxadiazole derivatives and investigated their anticonvulsant properties. Burbuliene et al. [8] have reported the synthesis and anti-inflammatory activity of derivatives of 5-[(2-disubstituted amino-6-methylpyrimidin-4-yl)-sulfonylmethyl]-3H-1,3,4-oxadiazole-2-thiones while Padmina et al. [9] have studied the synthesis and antioxidant activity of disubstituted 1,3,4-oxadiazole, 1,3,4-thiadiazoles, and 1,2,4-triazoles.

El-Emam et al. [10] have synthesized certain 5-(1-adamantyl)-2-substitutedthio-1-3-4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones and studied their anti-HIV-1 activity whereas synthesis and antitumor activity of some new 1,3,4-oxadiazo-ole, pyrazole, and pyrazolo[3,4-d]pyrimidine derivatives attached to 4-benzothiazole-2-yl phenyl moiety have been studied by El-Hamouly et al. [11].

Newton [12] patented the synthesis of novel N-aralkyl and N-heteroaralkyl amides of [1,3,4]-oxadiazole and [1,3,4] thiazole-carboxylic acids, which were further used for the preparation of herbicidal compositions containing compounds. He has developed a method of combating undesired plant growth using these compounds. Solak and
Rollas [13] have reported the synthesis and antituberculous activity of 2-(aryl/alkylamino)-5-(4-aminophenyl)-1,3,4-thiadiazoles and their Schiff bases whereas Matysiak et al. [14] have studied synthesis and antiproliferative activity of some 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Holla and coworker [15] carried out the synthesis of some new biologically active thiadiazolotriazinones while Radi et al. [16] have reported the discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.

Microwave-assisted chemical synthesis plays an important role in pharmaceuticals and medicinal chemistry such as drug discovery. The microwave mediated organic reactions are environmentally friendly, safe, rapid, and high yield compared to conventional methods.

2. Materials and Methods

The melting points were determined in open capillary tubes and are uncorrected. The IR spectra were recorded on Perkin-Elmer 157 spectrometer using KBr pellets. The H NMR spectra were scanned on a DRX-300 MHz spectrometer (300 MHz) in CDCl3/DMSO-d6 using TMS as internal standard and chemical shifts are expressed in δ ppm. Purity of synthesized compounds was checked by TLC using silica gel-G. Spots were exposed in an iodine chamber.

2.1. General Procedure for Preparation of Compounds (3a–f). The synthetic strategy of the target compounds is illustrated in Scheme 1. The diphenylacetic acid (1) (0.001 mol), hydrazine hydrate (0.001 mol), and ethanol (10 mL) were exposed in microwave at 5 sec. intervals. The specific reaction time of 3 min. was observed for diphenylacetic acid hydrazide (2). The product obtained was cooled in ice cooled water. The precipitate of the product obtained was filtered, washed with water, and purified by recrystallization from ethanol. Thereafter, the compound diphenylacetic acid hydrazide (2) (0.001 mol) and substituted aromatic acids (0.001 mol) were added together portionwise along with phosphorus oxychloride. After addition of these reactants, the reaction mixture was kept at room temperature for 5 min. Further, 3 g silica gel was added to it and it was properly mixed. It was irradiated in microwave at 5 sec. intervals. The specific reaction time of 2 min. was observed for compounds (3a–f). The product obtained was kept in crushed ice overnight. Next day, it was filtered, dried, and purified by recrystallization using ethanol. The completion of reaction was monitored by TLC method. The compounds (3a–f) were characterized with elemental analysis, IR, and NMR spectral data.

2-(5-Diphenylmethyl)-1,3,4-oxadiazol-2-yl)aniline (3a). Yield 78%, m.p. 115°C; IR (KBr) cm⁻¹: 1615 (C=N), 1218 (C–O–C), 3048 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 5.29 (IH, CH), 712–728 (Ar–H); Anal. Calcd. for C₁₂H₁₃N₂O: C, 66.14; H, 3.70; N, 11.02% Found: C, 66.02; H, 3.62; N, 11.07%.

2-(Diphenylmethyl)-5-phenyl-1,3,4-oxadiazole (3b). Yield 79%, m.p. 112°C; IR (KBr) cm⁻¹: 1615 (C=N), 1218 (C–O–C), 3048 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 5.33 (IH, CH), 706–725 (Ar–H); Anal. Calcd. for C₁₂H₁₃N₂O: C, 70.75; H, 5.16; N, 8.97%. Found: C, 70.67; H, 5.09; N, 8.90%.

2-[Diphenylmethyl]-1,3,4-oxadiazol-2-y1-phenol (3d). Yield 75%, m.p. 117°C IR (KBr) cm⁻¹: 1618 (C=N), 1216 (C–O–C), 3045 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 5.38 (IH, CH), 709–729 (Ar–H); Anal. Calcd. for C₁₃H₁₅N₂O: C, 76.81; H, 4.91; N, 8.53%. Found: C, 76.74; H, 4.86; N, 8.47%.

2-(Diphenylmethyl)-5-[2-phenylethenyl]-1,3,4-oxadiazole (3e). Yield 76%, m.p. 112°C; IR (KBr) cm⁻¹: 1620 (C=N), 1219 (C–O–C), 3049 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 5.28 (IH, CH), 714–730 (Ar–H); Anal. Calcd. for C₁₃H₁₅N₂O: C, 81.63; H, 5.36; N, 8.28%. Found: C, 81.56; H, 5.31; N, 8.24%.

2-Adamantan-1-yl-5-benzhydryl-[1,3,4]oxadiazole (3f). Yield 81%, m.p. 116°C; IR (KBr) cm⁻¹: 1619 (C=N), 1211 (C–O–C), 3041 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 5.36 (IH, CH), 710–732 (Ar–H); Anal. Calcd. for C₁₃H₁₅N₂O: C, 81.05; H, 7.07; N, 7.56%. Found: C, 81.01; H, 7.00; N, 7.49%.

2.2. General Procedure for Preparation of Compounds (6a–f). A mixture of diphenylacetic acid hydrazide (2) (0.001 mol), KOH (0.001 mol), and Cs₂ (5 mL) in ethanol (10 mL) was exposed to microwave at 5 sec. intervals. The specific reaction time of 3 min. was observed for 5-(diphenylmethyl)-1,3,4-oxadiazole-2-thiol (5). This reaction mixture was cooled and acidified with dil. HCl. The precipitate of product obtained was filtered, washed with water, and purified by recrystallization from ethanol. Thereafter, the compound (5) (0.001 mol) was added to the solution of NaOH (0.001 mol) and ethanol (10 mL) and these were mixed properly. Further, 2-chloro-N-(substituted phenyl)-acetamid (4) (0.001 mol) was added portionwise in the above reaction mixture. Then, this reaction mixture was irradiated with microwave at 5 sec. intervals for specific time (1 min.) to yield compound 6a–f. The product obtained was cooled. The precipitate of product was filtered, washed with water, and purified by recrystallization from ethanol.

2-(5-Benzhydryl-[1,3,4]oxadiazol-2-ylsulfanyl)-N-p-tolyl-acetamide (6a). Yield 77%, m.p. 115°C; IR (KBr) cm⁻¹: 3315 (NH), 1595 (C=O), 1660 (C=O), 1240 (C–O–C), 3042 (Ar–CH str.); ¹H NMR (DMSO δ) δ: 8.61 (IH, CONH), 5.32 (IH, CH), 3.92 (CH₃O), 710–722 (Ar–H); Anal. Calcd. for C₂₄H₂₃N₂O₃S: C, 69.37; H, 5.09; N, 10.11%. Found: C, 69.32; H, 5.02; N, 10.06%.

2-(5-Benzhydryl-[1,3,4]oxadiazol-2-ylsulfanyl)-N-(4-chlorophenyl)-acetamide (6b). Yield 81%, m.p. 112°C; IR (KBr) cm⁻¹: 3318 (NH), 1599 (C=O), 1666 (C=O), 1237 (C–O–C), 3039 (C=O).
Scheme 1: Synthesis of compounds (3a–f) and (6a–f).
(Ar–CH str.); 1H NMR (DMSO d6) δ: 8.64 (1H, CONH), 5.30 (1H, CH), 3.96 (CH3O) ppm. The CH3O protons were observed as singlet at δ = 3.90–3.99 ppm confirming the formation of acetamide derivatives. The CONH proton was observed as broad signals at δ = 8.58–8.66 ppm and multiplets of aromatic protons at δ = 7.08–7.30 ppm confirmed the formation of oxadiazole ring.

2-(5-Benzhydryl-[1,3,4]oxadiazol-2-ylsulfanyl)-N-(4-methoxy-phenyl)-acetamide (6e). Yield 77%, m.p. 121°C; IR (KBr) cm⁻¹: 3344 (NH), 1594 (C=N), 1665 (C=O), 1246 (C–O–C), 3049 (Ar–CH str.); 1H NMR (DMSO d6) δ: 8.56 (1H, CONH), 5.33 (1H, CH), 3.89 (CH3CO), 7.12–7.27 (Ar–H); Anal. Calcd. for C23H19N3O3S: C, 66.78; H, 4.17; N, 9.43%. Found: C, 66.88; H, 4.32; N, 9.55%.

Results and Discussion

The starting compound diphenylacetic acid hydrazide (2) reacts with substituted aromatic acids and POCl₃ under microwave irradiation to afford compounds (3a–f). Their structures were established on the basis of IR and 1H NMR spectral data. The IR spectra of (3a–f) exhibited absorption bands at 1615–1621 cm⁻¹ due to C=O stretching vibration. The peak at 1211–1219 cm⁻¹ appeared due to C–O–C stretching vibration. The 1H NMR spectra of these compounds revealed signals at δ = 5.28–5.36 ppm showing the presence of CH proton while a multiplet of aromatic protons at δ = 7.06–7.30 ppm confirmed the presence of oxadiazole ring.

A mixture of compound 5-(diphenylmethyl)-1,3,4-oxadiazole-2-thiol (5), solution of NaOH, ethanol, and 2-chloro-N-(substitutedphenyl)-acetamides (4) was irradiated in microwave to afford compounds (6a–f). The compounds showed absorption peak at 3318–3344 cm⁻¹ due to NH stretching vibrations. The peak at 1238–1246 cm⁻¹ appeared due to C–O–C stretching vibrations, C=O at 1659–1666 cm⁻¹ and C=N at 1594–1610 cm⁻¹. The 1H NMR spectra of these compounds displayed a singlet at δ = 5.31–5.37 ppm showing the presence of CH proton. The CH2CO protons were observed as singlet at δ = 3.90–3.99 ppm confirming the formation of acetamide derivatives. The CONH proton was observed as broad signals at δ = 8.58–8.66 ppm and multiplets of aromatic protons at δ = 7.08–7.30 ppm confirmed the formation of oxadiazole ring.

The results indicate that compounds show better antibacterial and antifungal activity. For antibacterial activity, the compound 3f exhibits good active against E. coli; 3e, 3f, and 6e exhibit good active against S. aureus showing MBC of 50 μg/mL; 3a, 6c, 6d, and 6e exhibit good active against P. aeruginosa showing MBC of 100 μg/mL. For antifungal activity, the compounds 3b and 3f exhibit good active against C. albicans; 3c, 3e, 6a, and 6e exhibit good active against A. niger; 3c, 3d, 3e, 3f, and 6d exhibit good active against A. clavatus showing MBC of 100 μg/mL.

4. Antibacterial and Antifungal Activity

All the compounds, that is, (3a–f) and (6a–f), were tested for antibacterial activity against Escherichia coli (Gram negative), Staphylococcus aureus (Gram positive), and Pseudomonas aeruginosa (Gram positive) bacteria and antifungal activity against three fungal strains Candida albicans, Aspergillus niger, and Aspergillus clavatus. Ampicillin and griseofulvin were used as standard drugs for antibacterial and antifungal activity, respectively.

Minimal bactericidal concentration (MBC) and minimal fungicidal concentration (MFC) were determined using Broth dilution method. Serial dilution for primary and secondary screening, material, and method was followed as per NCCLS-1992 manual [17].

A stock solution was prepared of each drug (2000 μg/mL concentration). In primary screening, 1000, 500, 250, and 125 μg/mL concentrations of the synthesized drugs were taken. The synthesized drugs found active in this primary screening were further tested in a second set of dilution against all microorganisms. The drugs found active in primary screening were similarly diluted to obtain 100, 50, 25, 12.5, 6.250, 3.125, and 1.5625 μg/mL concentrations. The standard drug used in the present study is ampicillin for evaluating antibacterial activity which showed 50, 50, and 100 μg/mL MBC against S. aureus, E. coli, and P. aeruginosa, respectively. Griseofulvin was used as the standard drug for antifungal activity, which showed 100 μg/mL MFC against all the species, used for the antifungal activity. The results of antimicrobial and antifungal activities of all the synthesized compounds are shown in Table I.
Table 1: Antibacterial and antifungal activity of all the synthesized compounds.

<table>
<thead>
<tr>
<th>Sr. number</th>
<th>Minimal bactericidal concentration (MBC) (μg/mL)</th>
<th>Minimal fungicidal concentration (MFC) (μg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gram negative</td>
<td>Gram positive</td>
</tr>
<tr>
<td></td>
<td>E. coli</td>
<td>P. aeruginosa</td>
</tr>
<tr>
<td>3a</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>3b</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>3c</td>
<td>500</td>
<td>250</td>
</tr>
<tr>
<td>3d</td>
<td>500</td>
<td>250</td>
</tr>
<tr>
<td>3e</td>
<td>250</td>
<td>250</td>
</tr>
<tr>
<td>3f</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>6a</td>
<td>500</td>
<td>250</td>
</tr>
<tr>
<td>6b</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>6c</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>6d</td>
<td>250</td>
<td>100</td>
</tr>
<tr>
<td>6e</td>
<td>500</td>
<td>250</td>
</tr>
<tr>
<td>6f</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>S.D.</td>
<td>50</td>
<td>100</td>
</tr>
</tbody>
</table>

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are thankful to the Head of Department of Chemistry, Pacific University, Udaipur (Raj.), for providing laboratory facilities and the Head of Department of Pharmacy for providing spectral and analytical data.

References


activity of some 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles, “European Journal of Medicinal Chemistry,” vol. 41, no. 4, pp. 475–482, 2006.


